Literature DB >> 12163215

Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia.

Marijke Brink1, Asif Anwar, Patrick Delafontaine.   

Abstract

Mechanisms that lead to cachexia are still poorly understood. The neurohormonal changes that occur in severe disease states may cause an imbalance between protein synthesis and degradation at the cellular level, followed by muscle wasting. Here, we review actions of angiotensin II, TNF-alpha, corticosteroids, insulin-like growth factor-I (IGF-I), and the IGF binding proteins, factors that may each contribute to the metabolic imbalance. The complex endocrine, autocrine and intracellular interactions between these factors will be described with examples from patient, rat and cell culture studies. Moreover, some of the data supporting that each of these hormones may directly affect cellular protein degradation mechanisms will be reviewed. Knowledge on these regulatory mechanisms will facilitate the development of new pharmaceutical strategies to treat cachexia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163215     DOI: 10.1016/s0167-5273(02)00239-5

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  11 in total

1.  Anaemia and heart failure.

Authors:  A J S Coats
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

2.  Angiotensin II-induced reduction in body mass is Ang II receptor mediated in association with elevated corticosterone.

Authors:  Rudy M Ortiz; Hiroyuki Kobori; Debra Conte; L Gabriel Navar
Journal:  Growth Horm IGF Res       Date:  2010-05-18       Impact factor: 2.372

3.  Angiotensin II upregulates protein phosphatase 2Cα and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting.

Authors:  A Michael Tabony; Tadashi Yoshida; Sarah Galvez; Yusuke Higashi; Sergiy Sukhanov; Bysani Chandrasekar; William E Mitch; Patrice Delafontaine
Journal:  Hypertension       Date:  2011-08-15       Impact factor: 10.190

4.  Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3.

Authors:  P Sarzi-Puttini; F Atzeni; J Schölmerich; M Cutolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

Review 5.  Cachexia in chronic heart failure: endocrine determinants and treatment perspectives.

Authors:  Norman Mangner; Yae Matsuo; Gerhard Schuler; Volker Adams
Journal:  Endocrine       Date:  2012-08-19       Impact factor: 3.633

Review 6.  [Obesity and cardiac cachexia in chronic heart failure].

Authors:  M Clauser; J Altenberger
Journal:  Herz       Date:  2013-09       Impact factor: 1.443

7.  Insulin resistance and muscle metabolism in chronic kidney disease.

Authors:  James L Bailey
Journal:  ISRN Endocrinol       Date:  2013-02-03

8.  Medical and nutritional implications in chronic heart failure: strengths and limitations.

Authors:  Lucero Rico-de la Rosa; Miguel Robledo-Valdez; Enrique Cervantes-Pérez; Gabino Cervantes-Guevara; Guillermo A Cervantes-Cardona; Sol Ramírez-Ochoa; Alejandro González-Ojeda; Clotilde Fuentes-Orozco; Ma Fernanda Padilla-Rubio
Journal:  Arch Cardiol Mex       Date:  2021

Review 9.  Cardiac cachexia: hic et nunc.

Authors:  Goran Loncar; Jochen Springer; Markus Anker; Wolfram Doehner; Mitja Lainscak
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-07-01       Impact factor: 12.910

Review 10.  Nutritional interventions for heart failure patients who are malnourished or at risk of malnutrition or cachexia: a systematic review and meta-analysis.

Authors:  Dina Habaybeh; Mariana Bordinhon de Moraes; Adrian Slee; Christina Avgerinou
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.